The U.S. Food and Drug Administration (FDA) has approved **OncoViva**, a novel therapy for advanced pancreatic ductal adenocarcinoma, marking the first new drug in this indication in over a decade. Clinical trial data demonstrated a 30% improvement in median overall survival compared with standard chemotherapy, extending life expectancy from 6.5 months to nearly 9 months. OncoViva works by targeting a previously undruggable KRAS G12D mutation, a common driver of pancreatic tumors. The approval is expected to provide a critical new option for patients with limited treatment choices, and the manufacturer has pledged to launch a patient‑assistance program to improve access.
On top of everything as it happens